Noveko International Announces Commitment Letter Finalizing Terms of $6 Million Financing

MONTREAL, Sept. 20, 2011 /CNW Telbec/ - Noveko International Inc. (TSX: EKO) (the "Company") is pleased to announce that it has finalized the terms and conditions of its previously announced $6 million financing.  Under the terms of a commitment letter issued by Toronto-based investment firm Third Eye Capital Corporation (the "Agent"), the Agent has undertaken to provide up to $4 million in credit facility and $2 million in convertible debentures. Both parties intend to close on or about September 26th, 2011 (the "Closing").

The credit facility will be a senior secured revolving facility in the amount of up to $4 million made available to the Company for a twenty four-month period from the Closing (the "Maturity Date"), and subject to the Company's right to terminate the credit facility after the first anniversary of the Closing. The senior secured convertible debentures in the aggregate amount of $2 million will be issued on the Closing date. Both the credit facility and the debentures will bear interest at an annual rate, compounded monthly, and paid monthly in arrears equal to a minimum of 12%, adjusted upward for any changes in a selected chartered bank prime rate. A 1% per annum standby fee, payable monthly in arrears, will also be due on the portion of the credit facility not disbursed.

The debenture holder shall have the right, at its sole discretion and at any time during the term, to convert, in whole or in part, the principal of the debentures into Class A shares of the Company, at a conversion price of 0.60$ per share. All advances under the credit facility, as well as the remaining non-converted portion of the debentures, shall be reimbursed by the Company on the Maturity Date. The remaining portion of the debentures, if any, would then be redeemable at 1.5 times their par value.

Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technologies, mainly air filters, surgical masks and respirators, as well as other products with antibacterial properties such as hand sanitizers - and the development, manufacturing and marketing of medical equipment, including portable real-time ultrasound scanners for use in human and veterinary medicine.

Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. Unless otherwise required under securities laws, the Company does not intend and undertakes no obligation to update or revise the forward-looking statements.


For further information:

Chantal Vennat, Director,
Investor Relations and Corporate Communications
Noveko International Inc.
Tel: (514) 875-0606

Profil de l'entreprise


Renseignements sur cet organisme


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.